C12N 2760/16234
Use of virus or viral component as vaccine
Official title: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2760/16234 (Use of virus or viral component as vaccine) appears on 393 US grants and 674 published applications in this corpus.
Search patents in C12N- Granted patents
- 393
- Published applications
- 674
- Assignees
- 273
- Inventors
- 1,114
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 2 | 0 |
| 1977 | 2 | 0 |
| 1978 | 1 | 0 |
| 1979 | 2 | 0 |
| 1980 | 2 | 0 |
| 1981 | 1 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 1 | 0 |
| 1985 | 1 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 1 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 2 | 0 |
| 1997 | 5 | 0 |
| 1998 | 5 | 0 |
| 1999 | 3 | 0 |
| 2000 | 4 | 0 |
| 2001 | 0 | 1 |
| 2002 | 4 | 0 |
| 2003 | 4 | 5 |
| 2004 | 3 | 11 |
| 2005 | 3 | 11 |
| 2006 | 2 | 16 |
| 2007 | 2 | 16 |
| 2008 | 6 | 18 |
| 2009 | 12 | 41 |
| 2010 | 3 | 30 |
| 2011 | 10 | 32 |
| 2012 | 12 | 36 |
| 2013 | 25 | 32 |
| 2014 | 21 | 37 |
| 2015 | 26 | 30 |
| 2016 | 32 | 42 |
| 2017 | 16 | 30 |
| 2018 | 30 | 28 |
| 2019 | 26 | 37 |
| 2020 | 22 | 40 |
| 2021 | 19 | 20 |
| 2022 | 24 | 35 |
| 2023 | 16 | 33 |
| 2024 | 15 | 42 |
| 2025 | 19 | 28 |
| 2026 | 9 | 23 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Mutant influenza B/Victoria lineage virus hemagglutinin proteins6 Oct 2026US 12,752,001 B2ModernaTX, Inc.
- Coronavirus and influenza compositions and methods for using them25 Aug 2026US 12,714,744 B2
- Vaccination of immunocompromised subjects4 Aug 2026US 12,697,382 B2Seqirus UK Limited
- Compositions and methods for membrane protein structure determination12 May 2026US 12,624,092 B2The Regents of the University of Michigan
- Universal influenza vaccine compositions21 Apr 2026US 12,605,439 B2Gylden Pharma Limited
- Influenza virus vaccines24 Sep 2026US 2026/0284174 A1Glaxosmithkline Biologicals SA
- Vaccination using high-density microprojection array patch17 Sep 2026US 2026/0273256 A1Vaxxas Pty Limited
- Influenza b virus mutants and uses therefor10 Sep 2026US 2026/0263586 A1FluGen, Inc.
- Nucleic acid influenza vaccines and respiratory virus combination vaccines27 Aug 2026US 2026/0248903 A1ModernaTX, Inc.
- Lipid particle compositions and methods of use thereof30 Jul 2026US 2026/0216313 A1Pfizer Inc.
Most cited
By later US patents
- Nucleic acid vaccines165US 9,872,900 B2ModernaTX, Inc. · 2018
- Viral liposome particle151US 4,261,975 AMerck & Co., Inc. · 1981
- Vaccine comprising a baculovirus produced influenza hemagglutinin protein fused to a second protein146US 5,858,368 AProtein Sciences Corporation · 1999
- Method for producing influenza hemagglutinin multivalent vaccines using baculovirus139US 5,762,939 AMg-Pmc, LLC · 1998
- Production of orthomyxoviruses in monkey kidney cells using protein-free media88US 6,146,873 ABaxter Aktiengesellschaft · 2000